Literature DB >> 27158344

Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis.

Ming-Xiang Zou1, Guo-Hua Lv1, Jing Li1, Xiao-Ling She2, Yi Jiang2.   

Abstract

Altered expression or activity of human telomerase reverse transcriptase (hTERT) has been associated with human carcinogenesis. This study detected hTERT expression in spinal chordoma tissues and associated the level of hTERT expression with clinicopathological data and patient survival. Tissue samples from 54 patients and 20 controls were subjected to immunohistochemical analysis of hTERT protein levels. hTERT expression levels were then analyzed for associations with patient survival rates and clinicopathological parameters (such as age, gender, tumor size, location, tumor grade, tumor stage, muscle invasion, recurrence or not, type of resection, tumor hemorrhage, tumor necrosis, levels of tumor-infiltrating lymphocytes (TILs) and Ki-67 expression). hTERT expression was detected in all 54 spinal chordomas. Expression levels were weak in 7, moderate in 17 and strong in 30 spinal chordoma tissue samples. In contrast, hTERT was rarely expressed in nucleus pulposus tissues (20 samples). hTERT expression was significantly associated with the Ki-67-staining index (t = -6.616, p < 0.001), TIL levels (F = 5.27, p = 0.008) and tumor invasion of the surrounding muscle tissue (t = -4.49, p < 0.001). Kaplan-Meier curves indicated that high hTERT expression was significantly associated with poor local recurrence-free survival of patients (χ(2) = 19.07, p < 0.001 via the log-rank test), but not associated with overall patient survival. Multivariate analysis of local recurrence-free survival demonstrated that hTERT expression was an independent prognostic factor among spinal chordoma patients (HR = 1.013, 95% CI: 1.002-1.024, p = 0.016). High hTERT expression was associated with spinal chordoma growth, invasion and poor patient prognosis. Future studies will investigate the use of hTERT as a biomarker to predict patient prognosis and disease progression or as a potential spinal chordoma therapy target.

Entities:  

Keywords:  Chordoma; biomarker; human telomerase reverse transcriptase (hTERT); prognosis

Year:  2016        PMID: 27158344      PMCID: PMC4846901     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  60 in total

1.  Oncologic and functional outcome following sacrectomy for sacral chordoma.

Authors:  Christopher A Hulen; H Thomas Temple; William P Fox; Andrew A Sama; Barth A Green; Frank J Eismont
Journal:  J Bone Joint Surg Am       Date:  2006-07       Impact factor: 5.284

2.  Operative management of sacral chordoma.

Authors:  Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

3.  Prognostic Factors in the Operative Management of Sacral Chordomas.

Authors:  Babar Kayani; Mathew David Sewell; Kimberly-Anne Tan; Sammy A Hanna; Richard Williams; Robin Pollock; John Skinner; Timothy W R Briggs
Journal:  World Neurosurg       Date:  2015-06-23       Impact factor: 2.104

4.  Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma.

Authors:  Ryutaro Sakabe; Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Akira Nakashima; Hiroki Ohge; Taijiro Sueda; Eiso Hiyama
Journal:  Ann Surg Oncol       Date:  2012-02-10       Impact factor: 5.344

5.  Expression of telomerase activity, human telomerase RNA, and telomerase reverse transcriptase in gastric adenocarcinomas.

Authors:  Jinyoung Yoo; Sonya Y Park; Seok Jin Kang; Byung Kee Kim; Sang In Shim; Chang Suk Kang
Journal:  Mod Pathol       Date:  2003-07       Impact factor: 7.842

6.  Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2.

Authors:  Lisa Lee-Jones; Irene Aligianis; Peter A Davies; Ana Puga; Peter A Farndon; Anat Stemmer-Rachamimov; Vijaya Ramesh; Julian R Sampson
Journal:  Genes Chromosomes Cancer       Date:  2004-09       Impact factor: 5.006

7.  High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

Authors:  David-Alexandre Gross; Stéphanie Graff-Dubois; Paule Opolon; Sébastien Cornet; Pedro Alves; Annelise Bennaceur-Griscelli; Olivier Faure; Philippe Guillaume; Hüseyin Firat; Salem Chouaib; François A Lemonnier; Jean Davoust; Isabelle Miconnet; Robert H Vonderheide; Kostas Kosmatopoulos
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 8.  The non-reverse transcriptase activity of the human telomerase reverse transcriptase promotes tumor progression (review).

Authors:  Yong Qin; Hong Guo; Bo Tang; Shi-Ming Yang
Journal:  Int J Oncol       Date:  2014-05-28       Impact factor: 5.650

9.  Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases.

Authors:  David L Smith; Jean-Charles Soria; Luc Morat; Qinghua Yang; Laure Sabatier; Diane D Liu; Rabih A Nemr; Asif Rashid; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2004-01       Impact factor: 5.344

10.  High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma.

Authors:  E Hiyama; H Yamaoka; T Matsunaga; Y Hayashi; H Ando; S Suita; H Horie; M Kaneko; F Sasaki; K Hashizume; A Nakagawara; N Ohnuma; T Yokoyama
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

View more
  6 in total

1.  Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Xiao-Bin Wang; Jing Li
Journal:  Eur Spine J       Date:  2016-10-18       Impact factor: 3.134

2.  Answer to the Letter to the Editor of J. Li et al. concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917).

Authors:  C Ruosi; G Colella; S L Di Donato; F Granata; M G Di Salvatore; F Fazioli
Journal:  Eur Spine J       Date:  2016-10-20       Impact factor: 3.134

3.  PIF1 Affects the Proliferation and Apoptosis of Cervical Cancer Cells by Influencing TERT.

Authors:  Jiancai Wang; Xiaoyan Zhu; Pian Ying; Yingping Zhu
Journal:  Cancer Manag Res       Date:  2020-08-25       Impact factor: 3.989

4.  Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma.

Authors:  Wei Huang; Yi-Guo Yan; Wen-Jun Wang; Zhi-Hua Ouyang; Xue-Lin Li; Tao-Lan Zhang; Xiao-Bin Wang; Bing Wang; Guo-Hua Lv; Jing Li; Ming-Xiang Zou
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

5.  Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels.

Authors:  Franco Rubino; Christopher Alvarez-Breckenridge; Kadir Akdemir; Anthony P Conley; Andrew J Bishop; Wei-Lien Wang; Alexander J Lazar; Laurence D Rhines; Franco DeMonte; Shaan M Raza
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

6.  Prognostic Significance of Tumor-Associated Macrophages in Chondroblastoma and Their Association with Response to Adjuvant Radiotherapy.

Authors:  Yi-Guo Yan; Ming-Xiang Zou; Bo-Wen Zheng; Min-Liang Yang; Wei Huang; Bo-Yv Zheng; Tao-Lan Zhang; Jing Li; Guo-Hua Lv
Journal:  J Inflamm Res       Date:  2021-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.